-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KjZ16DebdOxRIog7wsgYdI8XMBlQ4YMI+IongJB5w1aYeb1HUec3suKbcBgjXLGx nvYZBA3A0QGOlPBwUA6TaA== 0001127602-10-007298.txt : 20100303 0001127602-10-007298.hdr.sgml : 20100303 20100303191322 ACCESSION NUMBER: 0001127602-10-007298 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100301 FILED AS OF DATE: 20100303 DATE AS OF CHANGE: 20100303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AMPER LINDA E CENTRAL INDEX KEY: 0001220024 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15190 FILM NUMBER: 10655034 MAIL ADDRESS: STREET 1: C/O OSI PHARMACEUTICALS INC STREET 2: 58 S SERVICE RD CITY: MELVILLE STATE: NY ZIP: 11747 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OSI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000729922 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133159796 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 631-962-2000 MAIL ADDRESS: STREET 1: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: ONCOGENE SCIENCE INC DATE OF NAME CHANGE: 19920703 4 1 form4.xml PRIMARY DOCUMENT X0303 4 2010-03-01 0000729922 OSI PHARMACEUTICALS INC OSIP 0001220024 AMPER LINDA E C/O OSI PHARMACEUTICALS, INC. 41 PINELAWN ROAD MELVILLE NY 11747 1 Sr. VP, Human Resources Common Stock 2010-03-01 4 M 0 7370 38.01 A 26471 D Common Stock 2010-03-01 4 M 0 8499 23.83 A 34970 D Common Stock 2010-03-01 4 S 0 15869 55.20 D 19101 D Stock Option (Right to Buy) 38.01 2010-03-01 4 M 0 7370 0 D 2006-06-15 2012-06-14 Common Stock 7370 0 D Stock Option (Right to Buy) 23.83 2010-03-01 4 M 0 8499 0 D 2006-12-01 2012-11-30 Common Stock 8499 3001 D Transaction made pursuant to a Rule 10b5-1 trading plan adopted on November 24, 2008. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $55.15 to $55.39 per share. The Reporting Person will provide, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Stock option was accelerated on November 30, 2005 pursuant to the decision of the Compensation Committee of the Board of Directors to accelerate the vesting of all out-of-the-money stock options with an exercise price greater than $30 for all employees other than then-current executive officers. 25% of the stock options became exerciseable one year after the date of grant and the remainder vested ratably on a monthly basis over the succeeding 36 months. Includes only options with the same termination date. /s/ Pierre Legault, attorney-in-fact for Dr. Amper 2010-03-03 -----END PRIVACY-ENHANCED MESSAGE-----